BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Alesta Therapeutics for $275 million in upfront cash, securing an oral drug candidate that could mount the first serious challenge to AstraZeneca’s dominance in a rare bone disease market.
The deal, announced Tuesday, gives BioMarin control of ALE1, a small molecule in early-stage testing for hypophosphatasia, or HPP, a genetic condition that disrupts bone and dental mineralization. BioMarin will also pay up to $215 million in additional milestone payments tied to regulatory and development progress, with the transaction expected to close later this quarter.
The acquisition represents a strategic bet on an underserved segment of the HPP market. AstraZeneca’s Strensiq, the only approved therapy for the disease, generated approximately $1.7 billion in revenue in 2025, according to William Blair analyst Sami Corwin. But Strensiq is only FDA-approved for infantile- and juvenile-onset HPP, leaving adult patients without a targeted treatment option.
ALE1 is designed to fill that gap. Unlike Strensiq, an injectable enzyme replacement therapy that must be administered subcutaneously three to six times per week, ALE1 is an oral drug that lowers excess inorganic pyrophosphate, a key driver of the disease’s bone pathology. Alesta began a phase 1/2a trial in September, evaluating safety, tolerability, and pharmacodynamics in healthy volunteers and adults with HPP.
The adult focus is deliberate. AstraZeneca’s next-generation enzyme replacement therapy failed to meet its primary endpoint in a phase 3 trial involving patients 12 years and older, further widening the opportunity for a differentiated approach. If ALE1 succeeds, its oral administration and distinct mechanism could offer both convenience and cost advantages over injectable biologics.
William Blair resumed coverage of BioMarin with a Market Perform rating, describing ALE1 as a logical addition to the company’s portfolio with the potential to create meaningful long-term value. Corwin noted that while Strensiq replaces deficient tissue-nonspecific alkaline phosphatase, ALE1 targets the excess pyrophosphate that accumulates when that enzyme is missing, representing a fundamentally different biological strategy.
The deal is structured to minimize integration friction. Before closing, Alesta will spin out all non-ALE1 assets and its existing workforce into a newly formed entity. No Alesta employees will transfer to BioMarin, leaving the acquirer with a clean, focused asset.
BioMarin plans to finance the purchase entirely from existing cash reserves. The company expects the acquisition to have a modestly dilutive effect on full-year 2026 results, excluding the upfront payment, and will issue revised financial guidance upon closing.
ALE1 will join BioMarin’s skeletal condition unit, a division created during the company’s 2024 strategic overhaul. That unit already includes Voxzogo, an approved treatment for achondroplasia, the most common cause of dwarfism, along with clinical candidates targeting other skeletal diseases.
The acquisition also marks a course correction for BioMarin’s external growth strategy. The company recently terminated development of an enzyme replacement therapy for ENPP1 deficiency, an asset acquired through its $270 million takeover of Inozyme last year. That program was shelved after a phase 3 trial failure.
For BioMarin, the Alesta deal represents a calculated wager that a small molecule with a novel mechanism can succeed where enzyme replacement therapies have shown limitations. The company is betting that oral convenience, adult-market positioning, and differentiated biology can carve out a meaningful share of a market AstraZeneca has had largely to itself.